Therapeutic approaches to drug targets in atherosclerosis

Agnes, 2005 Alexander, 2011, Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study, The Journal of Urology, 185, 920, 10.1016/j.juro.2010.10.086 Amala, 2012, High platelet reactivity on clopidrogrel therapy correlates with increases coronary atherosclerosis and calcification, JACC: Cardiovascular Imaging, 5, 540 Andrea, 2003, Enhanced synthesis of the oxysterol 24(s), 25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation, Circulation Research, 93, 717, 10.1161/01.RES.0000097606.43659.F4 Anthony, 2005, LDL cholesterol: “bad” cholesterol, or bad science?, Journal of American Physicians and Surgeons., 10, 83 Anthony, 2005, Adventitial dysfunction: an evolutionary model for understanding atherosclerosis, Medical Hypotheses, 65, 962, 10.1016/j.mehy.2005.02.009 Barbara, 2011, Lifestyle and physiological risk factor profiles six weeks after an acute cardiac event: are patients achieving recommended targets for secondary prevention?, Heart, Lung and Circulation, 20, 446, 10.1016/j.hlc.2011.02.004 Bei, 2009, AMPK: an emerging drug target for diabetes and the metabolic syndrome, Cell Metabolism, 9, 407, 10.1016/j.cmet.2009.03.012 Bradford, 2002, The genetics of cerebrovascular atherosclerosis, Seminars in Cerebrovascular Diseases and Stroke, 2, 13 Wong, 2012, The biological role of inflammation in atherosclerosis, Canadial Journal of Cardiology, 28, 631, 10.1016/j.cjca.2012.06.023 Chandak, 2011, Lack of acyl CoA: diacylglycerolacyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout mice, Biochimica et Biophysica Acta, 1811, 1011, 10.1016/j.bbalip.2011.08.010 Claudio, 2001, Nitric oxide and atherosclerosis, Nitric Oxide, 5, 88, 10.1006/niox.2001.0337 Claudio, 2006, Nitric oxide and atherosclerosis: an update. Journal of Nitric Oxide, 15, 265, 10.1016/j.niox.2006.03.011 David Spence, 2007, Intensive management of risk factors for accelerated atherosclerosis: the role of multiple interventions, Current Neurology and Neuroscience Reports., 7, 42, 10.1007/s11910-007-0020-8 Elstad, 1995, P-selectin regulates platelet-activating factor synthesis and phagocytosis by monocytes, Journal of Immunology, 155, 2109 Eugene, 2004, Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects, Journal of Molecular and Cellular Cardiology., 37, 1137 Eva, 2010, Lipoprotein-associated phospholipase A2: a new therapeutic target, Canadian Journal of Cardiology, 26, 27A, 10.1016/S0828-282X(10)71058-8 Franc¸oise, 2009, Hypothyroidism is not associated with increased carotid atherosclerosis when cardiovascular risk factors are accounted for in hyperlipidemic patients, Atherosclerosis, 203, 269, 10.1016/j.atherosclerosis.2008.06.011 Francisco, 2012, Alternative splicing in endothelial senescence: role of the TGF-ß co-receptor endoglin, Senescence, 203, 953 Gerrity, 1997, The pathogenesis of atherosclerosis, Diabetologia, 40, S108, 10.1007/s001250051419 Pikuleva, 2006, Cholesterol-metabolizing cytochromes P450, Drug Metabolism and Disposition, 34, 513, 10.1124/dmd.105.008789 James, 2001, Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role?, FEMS Microbiology Letters, 197, 1, 10.1111/j.1574-6968.2001.tb10574.x Jeffrey, 2001, A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors, Journal of Medicinal Chemistry, 44, 851, 10.1021/jm000494a Jerzy, 2006, Leptin and atherosclerosis, Atherosclerosis, 189, 47, 10.1016/j.atherosclerosis.2006.03.003 John, 2000, Atherosclerosis: from lesion formation to plaque activation and endothelial function, Molecular Aspects of Medicine, 21, 99, 10.1016/S0098-2997(00)00005-4 John, 2005, Hypertension and atherosclerosis: clinical implications from the ALLHAT trial, Current Atherosclerosis Reports, 7, 132, 10.1007/s11883-005-0036-y John, 1998, An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits, Science, 282, 751, 10.1126/science.282.5389.751 John, 2010, Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk, Pharmacology & Therapeutics, 126, 314, 10.1016/j.pharmthera.2010.01.008 Rubin, 2012, Hyperglycemia and arterial stiffness: the atherosclerosis risk in the communities study, Atherosclerosis, 225, 246, 10.1016/j.atherosclerosis.2012.09.003 Kathryn, 2006, Scavenger receptors in atherosclerosis: beyond lipid uptake, Arteriosclerosis Thrombosis Vascular Biology, 26, 1702, 10.1161/01.ATV.0000229218.97976.43 Kathryn, 2001, DGAT2 is a new diacylglycerol acyltransferase gene family: purification, cloning, and expression in insect cells of two polypeptides from mortierella ramanniana with Diacylglycerol acyltransferase activity, The Journal of Biological Chemistry, 276, 38862, 10.1074/jbc.M106168200 Keith, 2010, Phospholipase A2s: developing drug targets for atherosclerosis, Atherosclerosis, 212, 357, 10.1016/j.atherosclerosis.2010.03.011 Kristina, 1996, Role of the peroxisome proliferator-activated Receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression, Journalof Lipid Research, 37, 907, 10.1016/S0022-2275(20)42003-6 Li, 2002, The macrophage foam cell as a target for therapeutic intervention, Nature Medicine, 8, 1235, 10.1038/nm1102-1235 Long, 2012, Effects of nasal immunization of multi-target preventive vaccines on atherosclerosis, Vaccine, 30, 1029, 10.1016/j.vaccine.2011.12.043 Margaret, 2010, Burden: mortality, morbidity and risk factors, Global Status Report On Noncommunicable Diseases Markus, 2012, Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in young finns study, Atherosclerosis, 223, 497, 10.1016/j.atherosclerosis.2012.05.036 Mervi, 2012, Atherosclerotic disease and risk factor modification in Saudi Arabia: a call to action, Journal of Vascular Health and Risk Management, 8, 349 Pablo, 2006, Inflammation, atherosclerosis, and cardiovascular diseaserisk: PAPP-A, Lp-PLA2, and Cystatin C. new insights or redundant information?, Revista Española de Cardiologia, 59, 247, 10.1157/13086082 Pao-Ling, 2002, Effects of menopause on intraindividual changes in serum lipids, blood pressure, and body weight- the Chin-Shan community cardiovascular cohort study, Atherosclerosis, 161, 409, 10.1016/S0021-9150(01)00644-X Paolo, 1995, Coronary and cerebrovascular atherosclerosis: two aspects of the same disease or two different pathologies?, Archives of Gerontology and Geriatrics, 20, 5 Paul, 1998, Oxidation of low density lipoproteins in the pathogenesis of Atherosclerosis, Atherosclerosis, 137, S33, 10.1016/S0021-9150(97)00305-5 Paul, 2002, Nongenomic actions of thyroid hormone on the heart, Thyroid, 12, 459, 10.1089/105072502760143827 Peter, 2008, Endoglin in angiogenesis and vascular diseases, Angiogenesis, 11, 79, 10.1007/s10456-008-9101-9 Petr, 2012, The role of endoglin in atherosclerosis, Atherosclerosis, 224, 4, 10.1016/j.atherosclerosis.2012.03.001 Philip, 2006, Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease, Journal of the American College of Cardiology, 47, 492, 10.1016/j.jacc.2005.09.042 Pieter, 2001, Molecular genetics and gene expression in atherosclerosis, International Journal of Cardiology, 80, 161, 10.1016/S0167-5273(01)00466-1 Qi Wei a, 2007, Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: Interaction with cigarette smoking, Atherosclerosis, 190, 26, 10.1016/j.atherosclerosis.2006.02.021 Qian, 2009, Role for porphyromonasgingivalis in the progression of atherosclerosis, Medical Hypotheses, 72, 71, 10.1016/j.mehy.2008.04.030 Robert, 2005, HDL-C and diabetic patient: target for therapeutic intervention, Diabetes Research and Clinical Practice, 68S2, S36 Ross, 1993, The pathogenesis of atherosclerosis: a perspective for the 1990s, Nature, 362, 801, 10.1038/362801a0 Ross, 1977, Response to injury and atherogenesis, TheAmerican Journal of Pathophysiology, 86, 675 Russo, 2002, Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis, Vascular Pharmacology, 38, 259, 10.1016/S1537-1891(02)00250-1 Sagar, 2012, Therapeutic approaches to drug targets in hyperlipidemia, Biomedicine., 2, 137, 10.1016/j.biomed.2012.08.002 Sainani, Gs., Talwalkar, Pg., Wadia, Rs., Keshvani, A.A., (2008) Hyperhomocysteinemia and its implications in atherosclerosis the Indian Scenario. Medicine, update. 12–20. Sandra, 2011, Perivascular adipose tissue as a cause of atherosclerosis, Atherosclerosis, 214, 3, 10.1016/j.atherosclerosis.2010.05.034 Sarah, 2009, Management of risk factors for accelerated atherosclerosis, Current Treatment Options in Neurology, 11, 460, 10.1007/s11940-009-0050-4 Steve, 2004, Genetic risk factors for stroke and carotidatherosclerosis: insights into pathophysiologyfrom candidate gene approaches, Lancet Neurology, 3, 227, 10.1016/S1474-4422(04)00708-2 Stuart, 1998, Discovery of 1-(4 Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl) 2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption, Journal of Medicinal Chemistry, 41, 973, 10.1021/jm970701f Tohru, 2002, Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters, British Journal of Pharmacology, 137, 561, 10.1038/sj.bjp.0704906 Toshihiro, 2010, Thyroid hormone and atherosclerosis, Vascular Pharmacology, 52, 151, 10.1016/j.vph.2009.09.004 Valentin, 2004, Monitoring of atherosclerosis, International Journal of Cardiology, 95, 39, 10.1016/j.ijcard.2003.03.018 Vasilios, 2011, Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment, The Open Cardiovascular Medicine Journal, 5, 24, 10.2174/1874192401105010024 Wen-Harn, 1995, Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan – a unique experience, Atherosclerosis, 118, 285, 10.1016/0021-9150(95)05616-5 Weyrich, 1995, Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation, Journal of Clinical Investigation, 95, 2297, 10.1172/JCI117921 Wilensky, 2007, The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation, Current Opinion in Cardiology, 22, 545, 10.1097/HCO.0b013e3282f028fe Williams, 1995, The response-to-retention hypothesis of early atherogenesis, Atherosclerosis, Thrombosis, and Vascular Biology, 15, 551, 10.1161/01.ATV.15.5.551